GenoMed Offers Trial for Influenza and Avian Influenza

Main Category: Bird Flu / Avian Flu
Also Included In: Flu / Cold / SARS
Article Date: 16 Oct 2005 - 0:00 PDT

email to a friend   printer friendly   opinions  

GenoMed (OTC Pink Sheets GMED), a Next Generation Disease Management company whose business is public health, announced today that it has begun Internet-based clinical trials for influenza and avian influenza, since the same treatment approach is expected to work for both kinds of virus.

There is currently no reliable vaccine or treatment for avian influenza. There are antiviral drugs and a vaccine for regular influenza, but they're far from perfect. The yearly influenza vaccine was recently reported to work in only a third of patients.

GenoMed's treatment has been 80% effective in a limited number of patients with West Nile virus encephalitis since 2003. The company is now ready to test it in viral pneumonias.

Any one interested in signing up for GenoMed's clinical trial just needs to go to GenoMed's website (genomed.com), and then click on "Company News" followed by "Investor Relations/Press Releases" followed by "Presentations" (in the upper right-hand corner). The trial documents are self-explanatory.

About GenoMed

GenoMed's broad-spectrum anti-viral approach was specifically mentioned in BioShield II, recently introduced in the US Senate (see Section 2151 of Senate bill S. 975).

Safe Harbor Statement

This press release contains forward looking statements, including those statements pertaining to GenoMed, Inc.'s (the Company's) finances and treatments. The words or phrases "ought to," "should," "could," "may," or similar expressions are intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those projected in the forward looking statements as a result of a number of risks and uncertainties, including but not limited to our research and development being subject to scientific, economic, regulatory, governmental, and technological factors. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. Unless otherwise required by applicable law, we specifically disclaim any obligation to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.

David W. Moskowitz MD
CEO, GenoMed
tel. 314.983.9933
dwmoskowitz@genomed.com
genomed.com

• Additional
• References
• Citations